Sino Biopharmaceutical (HK:1177) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sino Biopharmaceutical has received approval to submit a marketing application for its innovative drug combination, Benmelstobart Injection and Anlotinib Hydrochloride Capsules, aimed at treating the ultra-rare alveolar soft part sarcoma (ASPS). With a high tendency for metastasis and limited treatment options, this new combination therapy offers hope for improved outcomes in ASPS patients. This development marks a significant step for Sino Biopharmaceutical in expanding its portfolio of effective cancer treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.